Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8147556 | 0.81 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3MAOAMEN1 | |
| SCHEMBL13026656 | 0.76 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3MAOAMEN1 | |
| SCHEMBL4622110 | 0.74 | MEN1 (0.49) | SLC6A4SLC6A2SLC6A3MAOAMEN1 | |
| SCHEMBL83839 | 0.74 | ALDH1A1 (0.58) | SLC6A4SLC6A2SLC6A3MAOAMEN1 | |
| SCHEMBL257109 | 0.74 | MEN1 (0.55) | SLC6A4SLC6A2SLC6A3MAOAMEN1 | |
| SCHEMBL8134573 | 0.72 | MEN1 (0.46) | SLC6A4SLC6A2SLC6A3MAOAMEN1 | |
| SCHEMBL1145845 | 0.72 | IDO1 (0.52) | SLC6A4SLC6A2SLC6A3MAOAMEN1 | |
| SCHEMBL1145841 | 0.72 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3MAOAMEN1 | |
| SCHEMBL2092148 | 0.72 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3MAOAMEN1 | |
| SCHEMBL1006499 | 0.72 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3MAOAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446228-B2 | Thiophosphine compounds | ESSILOR INTERNATIONAL COMPAGNIE GENERALE D'OPTIQUE (FR) | 2008-11-04 | — | — | US | disclosed |
| US-7378556-B2 | Process for making thiophosphine compounds | ESSILOR INTERNATIONAL COMPAGNIE GENERALE D'OPTIQUE (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1608704-B1 | THIOPHOSPHINE COMPOUNDS AND METHOD OF MAKING POLYMERISABLE COMPOSITIONS CONTAINING THEM AND THEIR USE FOR MAKING OPHTALMIC LENSES | ESSILOR INT (FR) | 2008-03-19 | — | — | EP | disclosed |
| US-20070232834-A1 | THIOPHOSPHINE COMPOUNDS AND METHODS OF MAKING POLYMERIZABLE COMPOSITIONS CONTAINING THEM AND THEIR USE FOR MAKING OPHTHALMIC LENSES | ESSILOR INTERNATIONAL COMPAGNIE GENERALE D'OPTIQUE (FR) | 2007-10-04 | — | — | US | disclosed |
| US-20070232835-A1 | THIOPHOSPHINE COMPOUNDS AND METHODS OF MAKING POLYMERIZABLE COMPOSITIONS CONTAINING THEM AND THEIR USE FOR MAKING OPHTHALMIC LENSES | ESSILOR INTERNATIONAL COMPAGNIE GENERALE D'OPTIQUE (FR) | 2007-10-04 | — | — | US | disclosed |
| US-7129321-B2 | Thiophosphine compounds and methods of making polymerizable compositions containing them and their use for making ophthalmic lenses | ESSILOR INTERNATIONAL COMPAGNIE GENERALE D'OPTIQUE (FR) | 2006-10-31 | — | — | US | disclosed |
| EP-1608704-A2 | THIOPHOSPHINE COMPOUNDS AND METHOD OF MAKING POLYMERISABLE COMPOSITIONS CONTAINING THEM AND THEIR USE FOR MAKING OPHTALMIC LENSES | ESSILOR INTERNATIONAL COMPAGNIE GENERALE D'OPTIQUE (FR) | 2005-12-28 | — | — | EP | disclosed |
| US-20050107579-A1 | Thiophosphine compounds and methods of making polymerizable compositions containing them and their use for making ophthalmic lenses | ESSILOR INTERNATIONAL COMPAGNIE GENERALE D'OPTIQUE (FR) | 2005-05-19 | — | — | US | disclosed |
| WO-2004085447-A2 | THIOPHOSPHINE COMPOUNDS AND METHOD OF MAKING POLYMERISABLE COMPOSITIONS CONTAINING THEM AND THEIR USE FOR MAKING OPHTALMIC LENSES | ESSILOR INTERNATIONAL COMPAGNIE GENERALE D'OPTIQUE (FR) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232835-A1 | THIOPHOSPHINE COMPOUNDS AND METHODS OF MAKING POLYMERIZABLE COMPOSITIONS CONTAINING THEM AND THEIR USE FOR MAKING OPHTHALMIC LENSES | PHOSPHO1, TST, UACA | SLC6A4 3654/4885SLC6A2 4698/4885SLC6A3 4338/4885 |
| US-20070232834-A1 | THIOPHOSPHINE COMPOUNDS AND METHODS OF MAKING POLYMERIZABLE COMPOSITIONS CONTAINING THEM AND THEIR USE FOR MAKING OPHTHALMIC LENSES | PHOSPHO1, TST, UACA | SLC6A4 3654/4885SLC6A2 4698/4885SLC6A3 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.